2,249
Views
14
CrossRef citations to date
0
Altmetric
Articles

Gorham–Stout disease: good results of bisphosphonate treatment in 6 of 7 patients

, , , , , , , & show all

  • Adams D M, Trenor C C, Hammill A M, Vinks A A, Patel M N, Chaudry G, et al. Efficacy and safety of sirolimus in the treatment of complicated vascular anomalies. Pediatrics 2016; 137(2): e20153257–7.
  • Agyeman K, Pretell-Mazzini J, Subhawong T, Kerr DA, Jose J. Gorham disease. Am J Orthop 2017; 46(6): E458–62.
  • Boyer P, Bourgeois P, Boyer O, Catonné Y, Saillant G. Massive Gorham–Stout syndrome of the pelvis. Clin Rheumatol 2005; 24(5): 551–5.
  • Brance M L. Two cases of Gorham–Stout disease with good response to zoledronic acid treatment. CCMBM 2017; 14(2): 250–4.
  • Chan C K, Mohamed R-M, Azlina A A, Azhar M M. Multicentric disappearing bone disease treated with arthroplasty. Malays Orthop J 2016; 10(3): 42–5.
  • Dellinger M T, Garg N, Olsen B R. Viewpoints on vessels and vanishing bones in Gorham–Stout disease. Bone 2014; 63(C): 47–52.
  • Dunbar S F, Rosenberg A, Mankin H, Rosenthal D, Suit H D. Gorham’s massive osteolysis: the role of radiation therapy and a review of the literature. Int J Radiat Oncol Biol Phys 1993; 26(3): 491–7.
  • Ellati R, Attili A, Haddad H, Al-Hussaini M, Shehadeh A. Novel approach of treating Gorham–Stout disease in the humerus: case report and review of literature. Eur Rev Med Pharmacol Sci 2016; 20(3): 426–32.
  • García V, Alonso-Claudio G, Gómez-Hernández M-T, Chamorro A-J. Case report: Sirolimus on Gorham–Stout disease. Colomb Med Universidad del Valle; 2016; 47(4): 213–16.
  • Gorham L W, Stout A P. Massive osteolysis (acute spontaneous absorption of bone, phantom bone, disappearing bone): its relation to hemangiomatosis. J Bone Joint Surg Am 1955; 37-A(5): 985–1004.
  • Hagberg H, Lamberg K, Aström G. Alpha-2b interferon and oral clodronate for Gorham’s disease. Lancet 1997; 350(9094): 1822–3.
  • Hammer F, Kenn W, Wesselmann U, Hofbauer L C, Delling G, Allolio B, et al. Gorham–Stout disease: stabilization during bisphosphonate treatment. J Bone Miner Res 2005; 20(2): 350–3.
  • Heaver C, Isaacson A, Gregory J J, Cribb G, Cool P. Patient factors affecting the Toronto extremity salvage score following limb salvage surgery for bone and soft tissue tumors. J Surg Oncol 2016;113(7): 804–10.
  • Heyd R, Rabeneck D, Dörnenburg O, Tselis N, Zamboglou N. Gorham–Stout syndrome of the pelvic girdle treated by radiation therapy: a case report. Strahlenther Onkol 2011; 187(2): 140–3.
  • Kulenkampff H A, Richter G M, Hasse W E, Adler C P. Massive pelvic osteolysis in the Gorham–Stout syndrome. Int Orthop 1990; 14(4): 361–6.
  • Kuriyama D K, McElligott S C, Glaser D W, Thompson K S. Treatment of Gorham–Stout disease with zoledronic acid and interferon-α: a case report and literature review. J Pediatr Hematol Oncol 2010; 32(8): 579–84.
  • Li M-H, Zhang H-Q, Lu Y-J, Gao P, Huang H, Hu Y-C, et al. Successful management of Gorham–Stout disease in scapula and ribs: a case report and literature review. Orthop Surg 2018; 10(3): 276–80.
  • Liu Y, Zhong D-R, Zhou P-R, Lv F, Ma D-D, Xia W-B, et al. Gorham–Stout disease: radiological, histological, and clinical features of 12 cases and review of literature. Clin Rheumatol 2016; 35(3): 813–23.
  • Liu S, Zhou X, Song A, Kong X, Wang Y, Liu Y. Successful treatment of Gorham–Stout syndrome in the spine by vertebroplasty with cement augmentation. Medicine 2018; 97(29): e11555–6.
  • Ludwig K F, Slone T, Cederberg K B, Silva A T, Dellinger M. A new case and review of chylothorax in generalized lymphatic anomaly and Gorham–Stout disease. Lymphology 2016; 49(2): 73–84.
  • Mignogna M D, Fedele S, Russo Lo L, Ciccarelli R. Treatment of Gorham’s disease with zoledronic acid. Oral Oncol 2005; 41(7): 747–50.
  • Mo A Z, Trenor C C, Hedequist D J. Sirolimus therapy as perioperative treatment of Gorham–Stout disease in the thoracic spine: a case report. JBJS Case Connect 2018; 8(3): e70.
  • Möller G, Priemel M, Amling M, Werner M, Kuhlmey A S, Delling G. The Gorham–Stout syndrome (Gorham’s massive osteolysis). J Bone Joint Surg Br 1999; 81-B(3): 501–6.
  • Patel D V. Gorham’s disease or massive osteolysis. Clin Med Res 2005; 3(2): 65–74.
  • Patrick J H. Massive osteolysis complicated by chylothorax successfully treated by pleurodesis. J Bone Joint Surg Br 1976; 58-B(3): 347–9.
  • Ramaroli D A, Cavarzere P, Cheli M, Provenzi M, Barillari M, Rodella G, et al. A child with early-onset Gorham–Stout disease complicated by chylothorax: near-complete regression of bone lesions with interferon and bisphosphonate treatment. Horm Res Paediatr 2019; 10: 1–5.
  • Rauh G, Gross M. Disappearing bone disease (Gorham–Stout disease): report of a case with a follow-up of 48 years. Eur J Med Res 1997; 2(10): 425–7.
  • Reid I R. Bisphosphonates in the treatment of osteoporosis: a review of their contribution and controversies. Skeletal Radiol 2011; 40(9): 1191–6.
  • Tie M L, Poland G A, Rosenow E C. Chylothorax in Gorham’s syndrome: a common complication of a rare disease. Chest 1994; 105(1): 208–13.
  • Tunn P U, Pomraenke D, Goerling U, Hohenberger P. Functional outcome after endoprosthetic limb-salvage therapy of primary bone tumours: a comparative analysis using the MSTS score, the TESS and the RNL index. Int Orthop 2008; 32(5): 619–25.
  • Turra S, Gigante C, Scapinelli R. A 20-year follow-up study of a case of surgically treated massive osteolysis. Clin Orthop Relat Res 1990; (250): 297–302.
  • Wessel J H, Dodson T B, Zavras A I. Zoledronate, smoking, and obesity are strong risk factors for osteonecrosis of the jaw: a case-control study. J Oral Maxillofac Surg 2008; 66(4): 625–31.
  • Yerganyan V V, Body J J, De Saint Aubain N, Gebhart M. Gorham–Stout disease of the proximal fibula treated with radiotherapy and zoledronic acid. J Bone Oncol 2015; 4(2): 42–6.
  • Zanelli M, Zizzo M, Martino G, Bisagni A, De Marco L, Ascani S. Bone marrow biopsy disclosing a rare osteolytic disorder: Gorham–Stout syndrome. Int J Surg Pathol 2020; 28(1): 76–7 .